PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of “Moderate Buy” from Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $95.75.

Several research firms have issued reports on PTCT. Raymond James Financial assumed coverage on PTC Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $108.00 target price on the stock. Morgan Stanley upped their price objective on PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday. Wells Fargo & Company boosted their target price on shares of PTC Therapeutics from $93.00 to $106.00 and gave the stock an “overweight” rating in a research report on Friday. Citigroup raised shares of PTC Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $75.00 to $108.00 in a research note on Tuesday, June 9th. Finally, Royal Bank Of Canada boosted their price objective on shares of PTC Therapeutics from $82.00 to $85.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th.

Insider Activity

In other news, Director Mary L. Smith sold 15,834 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $90.00, for a total value of $1,425,060.00. Following the completion of the transaction, the director owned 21,813 shares in the company, valued at $1,963,170. This trade represents a 42.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Elliott Boulding sold 5,079 shares of PTC Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $85.08, for a total value of $432,121.32. Following the transaction, the vice president directly owned 105,272 shares of the company’s stock, valued at $8,956,541.76. This trade represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 198,662 shares of company stock worth $16,347,994. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UMB Bank n.a. acquired a new stake in shares of PTC Therapeutics in the fourth quarter valued at approximately $26,000. Comerica Bank raised its position in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in shares of PTC Therapeutics during the 4th quarter worth approximately $41,000. IFP Advisors Inc lifted its stake in PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 310 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in PTC Therapeutics by 63.8% during the 4th quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 247 shares during the last quarter.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $68.01 on Monday. The stock has a market capitalization of $5.64 billion, a P/E ratio of -117.26, a P/E/G ratio of 5.92 and a beta of 0.56. PTC Therapeutics has a 1 year low of $43.17 and a 1 year high of $90.87. The company’s fifty day moving average is $77.57 and its two-hundred day moving average is $72.71.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.68. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The business had revenue of $360.52 million for the quarter, compared to the consensus estimate of $298.63 million. During the same quarter in the previous year, the firm earned ($0.83) earnings per share. The business’s quarterly revenue was up 101.5% compared to the same quarter last year. Sell-side analysts predict that PTC Therapeutics will post 0.41 EPS for the current year.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.